羟氯喹与新冠病毒病：基于细胞与分子生物学的最新进展
Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.
作者信息
Pal Amit, Pawar Anil, Goswami Kalyan, Sharma Praveen, Prasad Rajendra
机构信息
Department of Biochemistry, AIIMS, Kalyani, 741235 West Bengal India.
Department of Zoology, DAV University, Jalandhar, 144012 Punjab India.
出版信息
Indian J Clin Biochem. 2020 Jul;35(3):274-284. doi: 10.1007/s12291-020-00900-x. Epub 2020 Jun 10.
Abstract
As the time for finding a definitive and safe cure as a vaccine for novel Corona Virus Disease 2019 (Covid-19) is still far, there is need to study in depth about the other potential drugs, which can save millions of lives due to Covid-19 pandemic. Right at the center of the debate is the use of drug "Hydroxychloroquine" as a prophylaxis as well as a treatment strategy against Covid-19 in conjunction with azithromycin. In this review, we will study the cellular and molecular aspects of hydroxychloroquine, which had driven its use in Covid-19 patients, as well as its chemistry and pharmacokinetics along with clinical trials going on worldwide using hydroxychloroquine against Covid-19.
摘要
由于找到一种确定且安全的新型冠状病毒肺炎（COVID-19）疫苗作为治愈方法的时间仍遥遥无期，因此有必要深入研究其他潜在药物，这些药物可以在COVID-19大流行中拯救数百万人的生命。争论的焦点正是药物“羟氯喹”作为预防措施以及与阿奇霉素联合用于治疗COVID-19的策略。在这篇综述中，我们将研究羟氯喹在COVID-19患者中使用的细胞和分子层面，以及它的化学性质、药代动力学，还有全球范围内正在进行的使用羟氯喹治疗COVID-19的临床试验。
相似文献
1
Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.
Indian J Clin Biochem. 2020 Jul;35(3):274-284. doi: 10.1007/s12291-020-00900-x. Epub 2020 Jun 10.
2
Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: What molecular dynamics studies of virus-host interactions reveal.
Int J Antimicrob Agents. 2020 Aug;56(2):106020. doi: 10.1016/j.ijantimicag.2020.106020. Epub 2020 May 13.
3
Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Jun 10;21(1):513. doi: 10.1186/s13063-020-04409-9.
4
Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents.
Med Hypotheses. 2021 Aug;153:110622. doi: 10.1016/j.mehy.2021.110622. Epub 2021 Jun 5.
5
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.
Trials. 2020 Jul 31;21(1):689. doi: 10.1186/s13063-020-04527-4.
6
Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: A systematic review and meta-analysis.
J Med Virol. 2020 Jul;92(7):776-785. doi: 10.1002/jmv.25898. Epub 2020 May 3.
7
Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.
Trop Med Infect Dis. 2020 Jul 3;5(3):112. doi: 10.3390/tropicalmed5030112.
8
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Clin Microbiol Infect. 2021 Jan;27(1):19-27. doi: 10.1016/j.cmi.2020.08.022. Epub 2020 Aug 26.
9
Hydroxychloroquine for the treatment and prophylaxis of COVID-19: The journey so far and the road ahead.
Eur J Pharmacol. 2021 Jan 5;890:173717. doi: 10.1016/j.ejphar.2020.173717. Epub 2020 Nov 3.
10
Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.
Trials. 2020 Oct 20;21(1):867. doi: 10.1186/s13063-020-04795-0.
引用本文的文献
1
Current Trends and Prospects for Application of Green Synthesized Metal Nanoparticles in Cancer and COVID-19 Therapies.
Viruses. 2023 Mar 13;15(3):741. doi: 10.3390/v15030741.
2
Spatiotemporal Differences of COVID-19 Infection Among Healthcare Workers and Patients in China From January to March 2020.
IEEE Access. 2021 Feb 9;9:28646-28657. doi: 10.1109/ACCESS.2021.3058155. eCollection 2021.
3
The utilization of hydroxychloroquine to reduce the main signs and symptoms of COVID-19 patients, a cross-sectional study.
Ann Med Surg (Lond). 2021 Oct;70:102867. doi: 10.1016/j.amsu.2021.102867. Epub 2021 Sep 16.
4
Exploring the Role of Heavy Metals and Their Derivatives on the Pathophysiology of COVID-19.
Biol Trace Elem Res. 2022 Jun;200(6):2639-2650. doi: 10.1007/s12011-021-02893-x. Epub 2021 Aug 27.
5
Novel corona virus (COVID-19); Global efforts and effective investigational medicines: A review.
J Infect Public Health. 2021 Jul;14(7):910-921. doi: 10.1016/j.jiph.2021.04.011. Epub 2021 May 1.
6
Immunopharmacological perspective on zinc in SARS-CoV-2 infection.
Int Immunopharmacol. 2021 Jul;96:107630. doi: 10.1016/j.intimp.2021.107630. Epub 2021 Apr 1.
7
COVID-19 pandemic: Can zinc supplementation provide an additional shield against the infection?
Comput Struct Biotechnol J. 2021;19:1371-1378. doi: 10.1016/j.csbj.2021.02.015. Epub 2021 Mar 2.
8
The Implications of Zinc Therapy in Combating the COVID-19 Global Pandemic.
J Inflamm Res. 2021 Feb 26;14:527-550. doi: 10.2147/JIR.S295377. eCollection 2021.
9
The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults.
J Clin Med. 2021 Feb 10;10(4):686. doi: 10.3390/jcm10040686.
10
Multi-Compartment Lymph-Node-on-a-Chip Enables Measurement of Immune Cell Motility in Response to Drugs.
Bioengineering (Basel). 2021 Jan 31;8(2):19. doi: 10.3390/bioengineering8020019.
本文引用的文献
1
The role of biomarkers in diagnosis of COVID-19 - A systematic review.
Life Sci. 2020 Aug 1;254:117788. doi: 10.1016/j.lfs.2020.117788. Epub 2020 May 13.
2
RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.
Lancet. 2020 May 22. doi: 10.1016/S0140-6736(20)31180-6.
3
Smooth or Risky Revisit of an Old Malaria Drug for COVID-19?
J Neuroimmune Pharmacol. 2020 Jun;15(2):174-180. doi: 10.1007/s11481-020-09923-w. Epub 2020 May 15.
4
SARS-CoV-2 Inflammatory Syndrome. Clinical Features and Rationale for Immunological Treatment.
Int J Mol Sci. 2020 May 10;21(9):3377. doi: 10.3390/ijms21093377.
5
Current practice and potential strategy in diagnosing COVID-19.
Eur Rev Med Pharmacol Sci. 2020 Apr;24(8):4548-4553. doi: 10.26355/eurrev_202004_21039.
6
High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.
Intensive Care Med. 2020 Jun;46(6):1089-1098. doi: 10.1007/s00134-020-06062-x. Epub 2020 May 4.
7
The Human Coronavirus Disease COVID-19: Its Origin, Characteristics, and Insights into Potential Drugs and Its Mechanisms.
Pathogens. 2020 Apr 29;9(5):331. doi: 10.3390/pathogens9050331.
8
COVID-19 cytokine storm: the interplay between inflammation and coagulation.
Lancet Respir Med. 2020 Jun;8(6):e46-e47. doi: 10.1016/S2213-2600(20)30216-2. Epub 2020 Apr 27.
9
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Circ Arrhythm Electrophysiol. 2020 Jun;13(6):e008662. doi: 10.1161/CIRCEP.120.008662. Epub 2020 Apr 29.
10
Updated diagnosis, treatment and prevention of COVID-19 in children: experts' consensus statement (condensed version of the second edition).
World J Pediatr. 2020 Jun;16(3):232-239. doi: 10.1007/s12519-020-00362-4. Epub 2020 Apr 24.
Zotero 插件